These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 11976828)

  • 21. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
    Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
    Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
    Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
    Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
    Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
    Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
    Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
    Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells].
    Chen XQ; Wan YF; Bai QX; Cao YX
    Ai Zheng; 2002 Apr; 21(4):356-9. PubMed ID: 12452010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma.
    Provencio M; Corbacho C; Salas C; Millan I; Espana P; Bonilla F; Ramon Cajal S
    Clin Cancer Res; 2003 Apr; 9(4):1406-11. PubMed ID: 12684412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
    Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
    Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.